Liminatus Pharma (NASDAQ:LIMN – Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.03) EPS for the quarter, FiscalAI reports.
Liminatus Pharma Trading Down 2.2%
NASDAQ LIMN traded down $0.00 during trading hours on Friday, reaching $0.18. The company had a trading volume of 754,434 shares, compared to its average volume of 1,005,395. The stock has a 50-day moving average of $0.20 and a 200 day moving average of $0.61. Liminatus Pharma has a 1-year low of $0.16 and a 1-year high of $33.66. The stock has a market capitalization of $8.08 million and a P/E ratio of -1.20.
Analyst Ratings Changes
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Liminatus Pharma in a report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.
Liminatus Pharma Company Profile
Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.
Read More
- Five stocks we like better than Liminatus Pharma
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Liminatus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liminatus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
